HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clerc, J. Articles by Barritault, L. Search for Related Content PubMed PubMed Citation Articles by Clerc, J. Articles by Barritault, L.

Influence of Dose Selection on Absorbed Dose Profiles in Radioiodine Treatment of Diffuse Toxic Goiters in Patients Receiving or Not Receiving Carbimazole

Departments of Nuclear Medicine, Biophysics and Biostatistics, Necker Hospital, Paris, France

Correspondence: For correspondence or reprints contact: J. Clerc, Service Central de Radio-Isotopes, Hôpital Necker Enfants-Malades, 149 Rue de Sévres, 75743 Paris, France.

ABSTRACT

We retrospectively reviewed the records of 224 patients with diffuse goiters treated with radioiodine, half of which received carbimazole. In all the cases, we carefully monitored the calculation of dosage. A lower percentage of early hypothyroidism but a higher failure rate was observed in the carbimazole subgroup. Nevertheless, after one year, a constant (4.5%) incremental rate of hypothyroidism was found regardless of carbimazole administration. Since we were able to precisely estimate the absorbed doses in our series, we evaluated by simulation the dosimetric profiles of nine methods of dose selection (MDS). These MDS were calibrated in such a way that the same threshold value of absorbed dose would always be reached at the thyroid level. We showed that the more elaborate the MDS, the more accurate the irradiation at the thyroid level and the lower the radiation dose administered. In patients not receiving carbimazole, a rapid MDS using modified early uptake measurements to predict the 24-hr actual value was found to be advisable. With patients receiving carbimazole and if a goal is to delay the occurrence of hypothyroidism, we advise MDS based on either a 48-hr uptake or on the calculation of the individual half-life.

This article has been cited by other articles:

				S. J. Bonnema, F. N. Bennedbaek, A. Veje, J. Marving, and L. Hegedus Continuous Methimazole Therapy and Its Effect on the Cure Rate of Hyperthyroidism Using Radioactive Iodine: An Evaluation by a Randomized Trial J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2946 - 2951. [Abstract] [Full Text] [PDF]

				S. J. Bonnema, F. N. Bennedbaek, A. Veje, J. Marving, and L. Hegedus Propylthiouracil before 131I Therapy of Hyperthyroid Diseases: Effect on Cure Rate Evaluated by a Randomized Clinical Trial J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4439 - 4444. [Abstract] [Full Text] [PDF]

				H. Jonsson and S. Mattsson Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism Radiat Prot Dosimetry, January 15, 2004; 108(2): 107 - 114. [Abstract] [Full Text] [PDF]

				V. A. Andrade, J. L. Gross, and A. L. Maia The Effect of Methimazole Pretreatment on the Efficacy of Radioactive Iodine Therapy in Graves' Hyperthyroidism: One-Year Follow-Up of a Prospective, Randomized Study J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3488 - 3493. [Abstract] [Full Text] [PDF]